On May 22, ImmunityBio fell 5.23% in regular trading, trading at $7.3285/share, with trading volume of $20.50 million. The stock has now declined for a second consecutive session following a 7.89% drop on May 21, as investors continue to take profits after a series of positive catalysts were rapidly priced in.

The selloff comes despite a dense cluster of fundamental developments. On May 17, the company signed an exclusive US agreement with Japan BCG Laboratory to import and commercialize the Tokyo-172 BCG strain for bladder cancer treatment. On May 18, ImmunityBio announced it received five US patents covering its ANKTIVA plus BCG combination therapy, valid through at least 2035. Additionally, at the AUA annual meeting on May 19, the company presented favorable efficacy comparison data for its Nai+BCG regimen versus Nadofaragene and TAR-200 in complete response rates.

Trading volume contracted notably from the prior session's $52.14 million, suggesting selling pressure is easing but buy-side conviction remains weak as the market digests the concentrated wave of positive news.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)